Recombinant human erythropoietin (rHuEPO) belongs to the therapeutic class of erythropoiesis stimulating agents (ESAs) due to its implication in the creation pathway of red blood cells and thus enhancement of oxygenation. Because of this bioactivity, rHuEPO has been considered as a major doping agent in sports competitions for decades. Over the years, doping control laboratories designed several analytical strategies applied to human and animal samples to highlight any misuse. Even though multiple analytical approaches have been reported, none has yet been dedicated to racing camels. Here, we describe an analytical strategy to test camel plasma samples at screening using an ELISA assay and a targeted nano‐liquid chromatography–high‐resolution tandem mass spectrometry for confirmatory analysis. The method was validated and has been successfully applied to post‐race samples, allowing the detection of a positive case of rHuEPO administration.

中文翻译：

---

重组人促红细胞生成素在赛骆驼兴奋剂控制中的筛选和验证性分析。

重组人促红细胞生成素（rHuEPO）由于其参与红细胞的生成途径并因此增强了氧合作用，因此属于促红细胞生成刺激剂（ESA）的治疗类别。由于这种生物活性，rHuEPO几十年来一直被认为是体育比赛中的主要掺杂剂。多年来，兴奋剂控制实验室设计了几种适用于人和动物样品的分析策略，以突出任何误用。尽管已经报道了多种分析方法，但还没有一种方法专门用于赛骆驼。在这里，我们描述了一种分析策略，即使用ELISA分析和靶向纳米液相色谱-高分辨率串联质谱法进行筛查，以测试骆驼血浆样品，以进行确认性分析。